article thumbnail

After a Speedy IPO, Equillium Expands Antibody R&D to Renal Disease

Xconomy

Headed by former Amylin CEO Dan Bradbury, Equillium (NASDAQ: EQ ) has licensed the drug, itolizumab, which it calls EQ001, from Indian pharma giant Biocon Limited for development in the United States and Canada. Equillium was formed to advance.